Table 1.
Baseline characteristics.
| Before propensity score matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
| NSAID (N = 398) | Acetaminophen (N = 2365) | SMD | NSAID (N = 397) | Acetaminophen (N = 397) | SMD | |
| Age group | ||||||
| 20–24 | 14.3 | 12.8 | 0.04 | 14.4 | 11.6 | 0.08 |
| 25–29 | 11.1 | 12.1 | − 0.03 | 11.1 | 13.6 | − 0.08 |
| 30–34 | 3.8 | 6 | − 0.1 | 3.8 | 5.3 | − 0.07 |
| 35–39 | 4 | 6.2 | − 0.1 | 4 | 6 | − 0.09 |
| 40–44 | 5.7 | 6 | − 0.01 | 5.6 | 5.8 | 0.01 |
| 45–49 | 9 | 8.2 | 0.03 | 9.1 | 10.6 | − 0.05 |
| 50–54 | 9.5 | 10.9 | − 0.04 | 9.6 | 8.1 | 0.05 |
| 55–59 | 10.6 | 9.2 | 0.04 | 10.6 | 9.1 | 0.05 |
| 60–64 | 8.3 | 8.8 | − 0.02 | 8.3 | 9.3 | − 0.04 |
| 65–69 | 5.5 | 6 | − 0.02 | 5.3 | 6 | − 0.03 |
| 70–74 | 3.3 | 4.6 | − 0.07 | 3.3 | 5.3 | − 0.1 |
| 75–79 | 6.3 | 3.6 | 0.12 | 6.3 | 3.5 | 0.13 |
| 80–84 | 3.3 | 2.7 | 0.04 | 3.3 | 2.8 | 0.03 |
| 85–89 | 3.8 | 2 | 0.11 | 3.8 | 2.5 | 0.07 |
| 90–94 | 1.5 | 0.9 | 0.05 | 1.5 | 0.5 | 0.1 |
| Sex: female | 58.3 | 60.8 | − 0.05 | 58.2 | 63.2 | − 0.1 |
| Medical history | ||||||
| Acute respiratory disease | 76.6 | 69.4 | 0.16 | 76.6 | 77.3 | − 0.02 |
| Chronic liver disease | 5.8 | 5.3 | 0.02 | 5.8 | 4.8 | 0.04 |
| Chronic obstructive lung disease | 2.5 | 1.9 | 0.04 | 2.5 | 0.8 | 0.14 |
| Dementia | 7.5 | 6.4 | 0.04 | 7.6 | 5.5 | 0.08 |
| Depressive disorder | 10.6 | 12 | − 0.04 | 10.6 | 9.3 | 0.04 |
| Diabetes mellitus | 16.8 | 18.2 | − 0.04 | 16.6 | 15.9 | 0.02 |
| Gastroesophageal reflux disease | 32.4 | 30.8 | 0.03 | 32.5 | 35.3 | − 0.06 |
| Gastrointestinal hemorrhage | 2 | 2.3 | − 0.02 | 2 | 1.3 | 0.06 |
| Hyperlipidemia | 31.4 | 32.5 | − 0.02 | 31.2 | 29.5 | 0.04 |
| Hypertensive disorder | 28.6 | 24.3 | 0.1 | 28.7 | 27.7 | 0.02 |
| Lesion of liver | 3.3 | 2.2 | 0.07 | 3.3 | 1.8 | 0.1 |
| Pneumonia | 27.6 | 34.4 | − 0.15 | 27.7 | 24.4 | 0.07 |
| Psoriasis | 1.8 | 0.9 | 0.08 | 1.8 | 1.3 | 0.04 |
| Renal impairment | 2.3 | 2.6 | − 0.02 | 2.3 | 3 | − 0.05 |
| Rheumatoid arthritis | 3.5 | 2.4 | 0.07 | 3.5 | 2.5 | 0.06 |
| Schizophrenia | 1.8 | 3.4 | − 0.1 | 1.8 | 1.5 | 0.02 |
| Urinary tract infectious disease | 5.8 | 5.3 | 0.02 | 5.8 | 4.8 | 0.04 |
| Viral hepatitis C | 0.3 | 0.5 | − 0.04 | 0.3 | 0.8 | − 0.07 |
| Visual system disorder | 41.2 | 36.1 | 0.1 | 41.1 | 35.5 | 0.11 |
| Medical history: cardiovascular disease | ||||||
| Atrial fibrillation | 1.3 | 0.9 | 0.04 | 1.3 | 0.8 | 0.05 |
| Cerebrovascular disease | 4.8 | 3 | 0.09 | 4.8 | 3.3 | 0.08 |
| Heart disease | 12.3 | 16.7 | − 0.13 | 12.3 | 13.1 | − 0.02 |
| Heart failure | 6 | 6.1 | 0 | 6 | 4.5 | 0.07 |
| Ischemic heart disease | ||||||
| Peripheral vascular disease | 9.3 | 7.9 | 0.05 | 9.1 | 8.3 | 0.03 |
| Venous thrombosis | 2 | 0.6 | 0.12 | 2 | 1 | 0.08 |
| Medical history: neoplasms | ||||||
| Malignant neoplastic disease | 4.5 | 4.9 | − 0.02 | 4.5 | 4 | 0.03 |
| Malignant tumor of breast | 0.5 | 0.7 | − 0.03 | 0.5 | 0.3 | 0.04 |
| Malignant tumor of colon | 0.3 | 0.5 | − 0.04 | 0.3 | 0.5 | − 0.04 |
| Malignant tumor of lung | 0.5 | 0.2 | 0.06 | 0.5 | 0.3 | 0.04 |
Data are presented as %.
RAAS renin–angiotensin–aldosterone system, SMD standardized mean difference.